PDF herunterladen
CC BY 4.0 · Rev Bras Ginecol Obstet 2020; 42(08): 511-518
DOI: 10.1055/s-0040-1716929
Febrasgo Position Statement

Premature ovarian insufficiency: A hormonal treatment approach

Number 2 - August 2020
Cristina Laguna Benetti-Pinto 
1   Departamento de Tocoginecologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
José Maria Soares Júnior 
2   Departamento de Obstetricia e Ginecologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
,
Gustavo Arantes Maciel 
2   Departamento de Obstetricia e Ginecologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
,
Andrea Prestes Nácul 
3   Hospital Fêmina, Grupo Hospitalar Conceição, Porto Alegre, RS, Brazil
,
Daniela Angerame Yela 
1   Departamento de Tocoginecologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
Ana Carolina Japur Sá Rosa e Silva 
4   Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Key points

  • Premature ovarian insufficiency (POI) is characterized by loss of ovarian function before the age of 40 years.

  • Diagnosis is based on follicle-stimulating hormone (FSH) levels >25 mIU/mL measured on two occasions (different samples) at least 4 weeks apart.

  • POI is suspected in the presence of irregular menstrual cycles or secondary amenorrhea in women before the age of 40 years, or in girls with primary amenorrhea.

  • Symptoms of hypoestrogenism are usually present, but this not mandatory.

  • Most POI cases are idiopathic, but they may also be due to autoimmune disease, genetic cause, oophorectomy, chemotherapy, radiation therapy (RT), and other less frequent causes.

  • POI is of genetic background in about 10% of cases, most commonly in patients with primary amenorrhea.

  • Chromosomal analysis (Karyotype) is indicated in non-iatrogenic POI cases. In the presence of Y chromosomal material, patients must be submitted to gonadectomy because of the high risk of gonadal tumours.

  • Despite being associated with infertility, spontaneous pregnancy may occur in 5% to 10% of POI cases,

  • Good therapeutic practices include providing guidance on a healthy lifestyle and sexual and psychological assessment and follow-up.

  • Hormonal treatment is mandatory for all POI-women with no contraindication , and it shall be continued until the usual age of menopause.

The National Specialty Commission for Gynecological Endocrinology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.




Publikationsverlauf

Artikel online veröffentlicht:
08. September 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Thieme Revinter Publicações Ltda
Rio de Janeiro, Brazil

 

  • References

  • 1 European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B. , et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31 (05) 926-37
    CrossrefPubMedGoogle Scholar
  • 2 Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360 (06) 606-14
    CrossrefPubMedGoogle Scholar
  • 3 Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008; 68 (04) 499-509
    CrossrefPubMedGoogle Scholar
  • 4 van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5 (05) 483-92
    CrossrefPubMedGoogle Scholar
  • 5 Hamoda H. British Menopause Society and Women’s Health Concern. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health 2017; 23 (01) 22-35
    CrossrefPubMedGoogle Scholar
  • 6 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67 (04) 604-6
    PubMedGoogle Scholar
  • 7 Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003; 18 (01) 199-206
    CrossrefPubMedGoogle Scholar
  • 8 Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol 2014; 124 (01) 193-7
    CrossrefPubMedGoogle Scholar
  • 9 Jiao X, Qin C, Li J, Qin Y, Gao X, Zhang B. , et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod 2012; 27 (07) 2201-7
    CrossrefPubMedGoogle Scholar
  • 10 Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril 2016; 106 (07) 1580-7
    CrossrefPubMedGoogle Scholar
  • 11 Jin M, Yu Y, Huang H. An update on primary ovarian insufficiency. Sci China Life Sci 2012; 55 (08) 677-86
    CrossrefPubMedGoogle Scholar
  • 12 De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010; 376 (9744): 911-21
    CrossrefPubMedGoogle Scholar
  • 13 Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol 2005; 6 (04) 209-18
    CrossrefPubMedGoogle Scholar
  • 14 Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S. , et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013; 5 (185) 185ra62
    CrossrefPubMedGoogle Scholar
  • 15 Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10 (03) 251-66
    CrossrefPubMedGoogle Scholar
  • 16 Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62 (03) 738-44
    CrossrefPubMedGoogle Scholar
  • 17 Koh JM, Kim CH, Hong SK, Lee KU, Kim YT, Kim OJ. , et al. Primary ovarian failure caused by a solvent containing 2-bromopropane. Eur J Endocrinol 1998; 138 (05) 554-6
    CrossrefPubMedGoogle Scholar
  • 18 Ayed W, Amouri A, Hammami W, Kilani O, Turki Z, Harzallah F. , et al. Cytogenetic abnormalities in Tunisian women with premature ovarian failure. C R Biol 2014; 337 (12) 691-4
    CrossrefPubMedGoogle Scholar
  • 19 Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open 2017 2017 (02) hox007
    PubMedGoogle Scholar
  • 20 Benetti-Pinto CL, de Almeida DM, Makuch MY. Quality of life in women with premature ovarian failure. Gynecol Endocrinol 2011; 27 (09) 645-9
    CrossrefPubMedGoogle Scholar
  • 21 de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011; 18 (03) 262-6
    CrossrefPubMedGoogle Scholar
  • 22 Committee on Gynecologic Practice. Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol 2017; 129 (05) e134-e141
    CrossrefPubMedGoogle Scholar
  • 23 Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Esteril 2016; 106 (07) 1588-99
    CrossrefPubMedGoogle Scholar
  • 24 Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991; 73 (02) 275-80
    CrossrefPubMedGoogle Scholar
  • 25 Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril 2008; 89 (02) 429-33
    CrossrefPubMedGoogle Scholar
  • 26 Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012; (08) CD000402
    PubMedGoogle Scholar
  • 27 Gazarra LBC, Bonacordi CL, Yela DA, Benetti-Pinto CL. Bone mass in women with premature ovarian insufficiency: a comparative study between hormone therapy and combined oral contraceptives. Menopause 2020; DOI: 10.1097/GME.0000000000001592.
    CrossrefPubMedGoogle Scholar
  • 28 World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva, Switzerland: WHO; 2015
    Google Scholar
  • 29 Elias AN, Pandian MR, Rojas FJ. Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls. Gynecol Obstet Invest 1997; 43 (01) 47-8
    CrossrefPubMedGoogle Scholar
  • 30 Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update 2012; 18 (04) 405-19
    CrossrefPubMedGoogle Scholar
  • 31 Soman M, Huang LC, Cai WH, Xu JB, Chen JY, He RK. , et al. Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis. Menopause 2019; 26 (01) 78-93
    CrossrefPubMedGoogle Scholar
  • 32 Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015; 18 (04) 483-91
    CrossrefPubMedGoogle Scholar
  • 33 Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH. , et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99 (10) 3489-510
    CrossrefPubMedGoogle Scholar
  • 34 Weiss RV, Hohl A, Athayde A, Pardini D, Gomes L, Oliveira M. , et al. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab 2019; 63 (03) 190-8
    CrossrefPubMedGoogle Scholar
  • 35 Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA. , et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165 (014) 1582-9
    CrossrefPubMedGoogle Scholar
  • 36 Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A. , et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105 (5 Pt 1): 944-52
    CrossrefPubMedGoogle Scholar
  • 37 Davis SR, Baber R, Panay N, Bitzer J, Cerdas Perez S. , et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women [published correction appears in Climacteric. 2019 Dec;22(6):637]. Climacteric 2019; 22 (05) 429-34
    CrossrefPubMedGoogle Scholar
  • 38 Sa MF, Benetti-Pinto CL. Insuficiencia ovariana prematura. Federacao Brasileira das Associacoes de Ginecologia e Obstetricia (Febrasgo), Sao Paulo, 2018. (Protocolo Febrasgo de Ginecologia no 43 da Comissao Nacional Especializada em Ginecologia Endocrina)
    PubMed
  • 39 Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO. , et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177 (03) G1-G70
    CrossrefPubMedGoogle Scholar
  • 40 Practice Committee of American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril 2012; 97 (02) 282-4
    PubMedGoogle Scholar